(600812)"North China Pharmaceutical Company Ltd."Announcement on Abnormal Fluctuations in Stock Trading
Filed with SSE · Stock code 600812 · · 3 pages · Chinese
Summary by 6ix AI
North China Pharmaceutical Company Ltd. has issued an announcement regarding abnormal fluctuations in its stock trading, noting significant price changes over three consecutive trading days, which is classified as abnormal according to exchange rules. The company conducted an internal review and confirmed that there are no undisclosed significant matters affecting its operations or stock price. The board of directors has stated that all disclosed information is accurate and complete, and there are no other undisclosed matters that could impact the stock's trading price.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
North China Pharmaceutical Company Ltd. on 6ix
Story so far
- Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Hebei Jurisdiction and 2026 Semi-annual Collective Performance Briefing
- Announcement on Providing Guarantees for Subsidiaries
- Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Subordinate Company
Earlier from North China Pharmaceutical
- Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Hebei Jurisdiction and 2026 Semi-annual Collective Performance Briefing
- Announcement on Providing Guarantees for Subsidiaries
- Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Subordinate Company
- Semi-annual Report for 2026
- Announcement on Resignation of Senior Management
Later from North China Pharmaceutical
All North China Pharmaceutical news releasesFollow North China Pharmaceutical into a list and get an email when it puts out news.
Follow North China Pharmaceutical